1. Home
  2. PRLD vs FEBO Comparison

PRLD vs FEBO Comparison

Compare PRLD & FEBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • FEBO
  • Stock Information
  • Founded
  • PRLD 2016
  • FEBO 1993
  • Country
  • PRLD United States
  • FEBO Hong Kong
  • Employees
  • PRLD N/A
  • FEBO N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • FEBO
  • Sector
  • PRLD Health Care
  • FEBO
  • Exchange
  • PRLD Nasdaq
  • FEBO Nasdaq
  • Market Cap
  • PRLD 48.6M
  • FEBO 12.6M
  • IPO Year
  • PRLD 2020
  • FEBO 2023
  • Fundamental
  • Price
  • PRLD $0.78
  • FEBO $1.08
  • Analyst Decision
  • PRLD Strong Buy
  • FEBO
  • Analyst Count
  • PRLD 2
  • FEBO 0
  • Target Price
  • PRLD $4.50
  • FEBO N/A
  • AVG Volume (30 Days)
  • PRLD 224.4K
  • FEBO 14.3K
  • Earning Date
  • PRLD 08-11-2025
  • FEBO 07-15-2025
  • Dividend Yield
  • PRLD N/A
  • FEBO N/A
  • EPS Growth
  • PRLD N/A
  • FEBO N/A
  • EPS
  • PRLD N/A
  • FEBO N/A
  • Revenue
  • PRLD $7,000,000.00
  • FEBO $17,110,653.00
  • Revenue This Year
  • PRLD N/A
  • FEBO N/A
  • Revenue Next Year
  • PRLD N/A
  • FEBO N/A
  • P/E Ratio
  • PRLD N/A
  • FEBO N/A
  • Revenue Growth
  • PRLD N/A
  • FEBO 11.58
  • 52 Week Low
  • PRLD $0.61
  • FEBO $0.90
  • 52 Week High
  • PRLD $6.80
  • FEBO $17.00
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 42.16
  • FEBO 47.86
  • Support Level
  • PRLD $0.77
  • FEBO $0.90
  • Resistance Level
  • PRLD $0.84
  • FEBO $1.26
  • Average True Range (ATR)
  • PRLD 0.07
  • FEBO 0.08
  • MACD
  • PRLD -0.02
  • FEBO -0.00
  • Stochastic Oscillator
  • PRLD 16.04
  • FEBO 49.44

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About FEBO Fenbo Holdings Limited

Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.

Share on Social Networks: